Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer

Authors :: Filiz Çay Şenler
Hakan Akbulut
Onay Gercik
Ahmet Demirkazik
Dilsa Mizrak
Handan Onur
Güngör Utkan
Fikri Icli
Source :: Journal of Clinical Oncology. 33:e14681-e14681
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e14681 Background: Monoclonal antibodies targeting either VEGF or EGFR have improved the treatment outcomes in patients with advanced colorectal cancer (CRC). Although cetuximab or panitumumab are ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Cetuximab
Bevacizumab
business.industry
medicine.drug_class
Treatment outcome
Wild type
Monoclonal antibody
digestive system diseases
Advanced colorectal cancer
Internal medicine
medicine
Panitumumab
In patient
business
neoplasms
medicine.drug

Tools